Investment PowerPlay: I Think The Market is On Fentanyl
Company
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.
The Recent Drop
Emergent BioSolutions (NYSE: EBS) stock plummeted approximately 20% to 27% on February 27-28, 2026, after the company released weak 2026 revenue guidance ($720M–$760M vs. $1.16B estimate) and missed Q4 2025 earnings expectations. The decline was also driven by lower demand for Narcan (naloxone).
Key details regarding the stock decline:
- The market didn’t like to hear the announcement of operational headwinds from management. The earnings call mentioned a “major negative reset” in 2026 expectations.
- Q4 2025 Earnings Miss: The fourth-quarter results showed a
24% year-over-year revenue decline to $148.7 million and a non-GAAP loss per share of
- Naloxone Competition: Sales of Narcan; the company’s overdose-reversal nasal spray, dropped
41% in Q4 2025 due to increased market competition.
Now the Good News
One Day Earlier
Emergent BioSolutions announced multi-year contracts and a contract modification with the Public Health Agency of Canada and Department of National Defence valued at up to approximately CAD 140 million. Emergent expects more than CAD 35 million in orders in 2026 and will supply four medical countermeasures, several made at its Health Canada–licensed facility to strengthen domestic production and surge capacity.
Two Days Prior: Share Buyback
Emergent BioSolutions Inc. announced that its Board of Directors authorized the repurchase of up to $50 million of the company’s common stock on or before March 31, 2027. This authorization replaces the prior repurchase authorization which permitted Emergent to repurchase up to $50 million of company’s common stock by March 27, 2026. Under the prior authorization, Emergent repurchased $24.8 million shares. The remaining amounts to over 5% of their shares.
Last Week
Emergent BioSolutions Inc. announced it is teaming up with football icon, Emmitt Smith, to break down the stigma around opioid use and accidental overdose, which continues to fuel a national epidemic impacting people from all walks of life.
During his decorated 15-year professional career, Smith faced multiple injuries and often chose to play through the pain, because he knew the risks associated with opioids as he witnessed promising athletes develop a dependency, lost teammates to accidental overdose and watched loved ones struggle. Emergent, along with Smith, are launching Ready to Rescue to create open dialogue about opioid risks and educate the public on how to be prepared to help save a life in an opioid overdose emergency.
Outside of the larger macro play…this is an unusual opportunity for us given that there has been 3 positive announcements back to back to back recently and yet the stock still took a big hit on missed earnings and revenues
A Closer Look
📌Profitability
Revenue & Profitability (Dec 31st 2025)
- Total revenue: $742.9 million (vs. $1,043.6M in 2024)
- Net income: $52.6 million (turned profitable from a $190.6M loss prior year)
- Diluted EPS: $0.93 (compared to –$3.60 in 2024)
- Adjusted EBITDA: $205.0 million
- Gross margin: ~45% (adjusted: ~54%)
Costs & Expenses (2025)
- R&D: $53.2 M
- SG&A: $186.1 M
- Total product & service cost of sales: $326.2 M
Products
1. NARCAN® Nasal Spray is also widely available nationwide as the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose.
NARCAN® Nasal Spray 4 mg (naloxone HCl)
KLOXXADO®* Nasal Spray 8 mg (naloxone HCl)
2. Medical Countermeasures: For over 25 years, Emergent has been at the forefront of preparedness, working hand in hand with governments and agencies to deliver products that protect against some of the world’s most pressing health threats.
A. ACAM2000®
(Smallpox and Mpox (Vaccinia) Vaccine, Live)
B. ANTHRASIL®
[Anthrax Immune Globulin Intravenous (Human)]
C. BAT®
[Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)]
D. BioThrax® This one is huge because they have secured defense contracts for this vaccine… and does anyone else smell mass recruitment for war??
(Anthrax Vaccine Adsorbed)
E. CNJ-016®
(vaccinia immune globulin intravenous, human)
F. CYFENDUS®
(Anthrax Vaccine Adsorbed, Adjuvanted)
G. Ebanga™* (ansuvimab-zykl)
H. raxibacumab injection
A fully human monoclonal antibody
I. TEMBEXA®
(brincidofovir)
Specifics
A Reading Break! I have my investment management company up and running–if you’re interested in investing you’ll have to contact me directly.
Some performance above via one managed LLC
Financials
| Gross Margin % | 52.14 |
| Operating Margin % | 15.79 |
| Net Margin % | 10.11 |
| EBITDA Margin % | 35.11 |
| FCF Margin % | 0.19 |
| ROE % | 14.25 |
| ROA % | 5.29 |
| ROIC % | 7.24 |
Profitable and holds lower than market valuations.
Some Runway of Balance Sheet Support (Dec 31st, 2025)
Cash & equivalents: approximately $205 M (solid liquidity position)
Gross debt: reduced to ~$590 M (~32% reduction compared to 2023). In late December 2025, Emergent voluntarily prepaid $100 million of its outstanding term loan principal using cash on hand. This is part of a deliberate effort to reduce leverage and strengthen the balance sheet
Net leverage: ~1.9× adjusted EBITDA (improved materially)
Assets & Liabilities
Total assets: ~$1.5 B
Total liabilities: ~$878.5 M
This reflects a healthy liquidity cushion and strengthened balance sheet compared with recent years, aided by operating cash flow and debt reduction actions
The Macro Play
1. National Health Security & Biodefense
- The company supplies vaccines and antitoxins for smallpox, anthrax, botulism, and other biological threats—critical for government preparedness.
- Governments maintain stockpiles of these products as part of national defense frameworks, often under long-term contracts.
2. Opioid Emergency Response
- Naloxone (e.g., NARCAN®) remains a critical first-response drug for opioid overdoses in the U.S. and globally. Demand persists due to ongoing opioid crises, even as competition grows.
3. Government Backing & Mandates
- Public health agencies (e.g., U.S. government, international partners) prioritize biodefense readiness and will continue procuring countermeasures.
- Institutional purchase cycles and strategic stockpile replenishment provide baseline demand across product lines.
For instance, just last year ~$56 M was allocated for ACAM2000® smallpox/mpox vaccine with HHS/ASPR and ~$30 M CYFENDUS® anthrax vaccine option from BARDA–these are renewed annually.
I have covered here (click the buttons) regarding the severity of the fentanyl crisis in the United States… it’s not going away just because Trump orders some Delta Force to take out some head-honchos in Michoacán. It’s a real, growing attack upon the American citizenry.
You could say that I believe we will be in a period of increased “countermeasures” moving forward. Whether this be positive (state investing directly into highly needed sectors, commodities or military personnel) or negative (the state trying to remove something such as homeless, criminal actors or drug-users)–both will create chaos and demand. I often think like a contrarian that the world is far different than the headlines promote–and that trends in motion tend to stay in motion. Their naloxone product sales are not going away.
Closing
I’ve been following Emergent BioSolutions for a little bit of time now–I’ve been hoping that it would get lumped into some overvaluation pullbacks and therefore be picked up for bargain prices–and perhaps now we have that moment. I distinctly remember this company as being interesting given its valuations, and products that seemingly would create stable revenues in an increasingly unstable world [especially one at war].
Notwithstanding the blunt news of poor guidance, missed revenues and a major hit to sales of Narcan, I believe that Emergent has the improving balance sheet, the products and the potential for future contracts (given the sorry state of the world) at reasonable valuations to weather the storm over the long-run.
If you’re into trading, consider other plays–however if you’re looking to speculate at which companies will survive the next financial collapse, I’d recommend considering going against the grain and taking a look at $EBS.
Perhaps the market is high, in a sensory sense of the word–and ironically they could use some of Emergent’s products to come back to reality.
What do you think?
I remind you again to pick up my free WEEKLY WEIGH IN newsletter by posting your email above and subscribe for more stock picks like this one (affordable given the information contained)!
